{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:54Z","timestamp":1787008614645,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Global Health Delivery","award":["K24AI114444"],"award-info":[{"award-number":["K24AI114444"]}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Completion of tuberculosis (TB) preventive treatment is important to optimize efficacy; treatment-related adverse events (AEs) sometimes result in discontinuation. This study describes the occurrence of AEs and their risk factors during a 6-month, 2-drug, fluoroquinolone-based preventive treatment for household contacts of patients with drug-resistant TB in Karachi, Pakistan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary outcome was development of any clinical AE during preventive treatment. Adverse events were categorized using the AE grading tables of the National Institutes of Health. Time-to-event analysis with Kaplan-Meier curves and Cox proportional hazards models accounting for recurrence were used to analyze associated risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 172 household contacts on preventive treatment, 36 (21%) developed 64 AEs during 813 months of treatment. The incidence of AEs over 6 months of treatment was 7.9 per 100 person-months; 16 per 100 person-months with a fluoroquinolone and ethionamide, and 4.4 per 100 person-months with a fluoroquinolone and ethambutol. There were 53 (83%) grade 1 and 11 grade 2 AEs, with no grade 3 or 4 AEs. In multivariable analysis, the risk of AEs was higher in contacts prescribed ethionamide as compared to ethambutol adjusting for age, sex, and body mass index (adjusted hazard ratio, 2.1 [95% confidence interval {CI}, 1.2\u20133.6]). Overall, there was no notable difference in treatment completion among the contacts who experienced an AE and those who did not (crude odds ratio, 1.1 [95% CI, .52\u20132.5]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A fluoroquinolone-based preventive treatment regimen for drug-resistant TB exposure is well tolerated. Regimens with ethionamide are more likely to result in AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa327","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T16:11:26Z","timestamp":1585066286000},"page":"1709-1715","source":"Crossref","is-referenced-by-count":12,"title":["Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-9916","authenticated-orcid":false,"given":"Amyn A","family":"Malik","sequence":"first","affiliation":[{"name":"Emory University Rollins School of Public Health, Atlanta, Georgia, USA"},{"name":"Global Health Directorate, Indus Health Network, Karachi, Pakistan"},{"name":"Interactive Research and Development Global, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes C","family":"Becerra","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Partners In Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L","family":"Lash","sequence":"additional","affiliation":[{"name":"Emory University Rollins School of Public Health, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Cranmer","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad B","family":"Omer","sequence":"additional","affiliation":[{"name":"Yale Institute for Global Health, New Haven, Connecticut, USA"},{"name":"Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Yale School of Public Health, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Fuad","sequence":"additional","affiliation":[{"name":"Global Health Directorate, Indus Health Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Global Health Directorate, Indus Health Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Amanullah","sequence":"additional","affiliation":[{"name":"Indus Hospital, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jaswal","sequence":"additional","affiliation":[{"name":"Global Health Directorate, Indus Health Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Salahuddin","sequence":"additional","affiliation":[{"name":"Indus Hospital, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Partners In Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidah","family":"Hussain","sequence":"additional","affiliation":[{"name":"Interactive Research and Development Global, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel R","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Emory University Rollins School of Public Health, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"2021072716592491700_CIT0001","volume-title":"Global tuberculosis control report 2018","author":"World Health Organization","year":"2018"},{"key":"2021072716592491700_CIT0002","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cit643","article-title":"Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis","volume":"58","author":"Shah","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021072716592491700_CIT0003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/aje\/152.3.247","article-title":"Lifetime risks, incubation period, and serial interval of tuberculosis","volume":"152","author":"Vynnycky","year":"2000","journal-title":"Am J Epidemiol"},{"key":"2021072716592491700_CIT0004","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","article-title":"Tuberculosis","volume":"362","author":"Frieden","year":"2003","journal-title":"Lancet"},{"key":"2021072716592491700_CIT0005","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.5588\/ijtld.10.0781","article-title":"Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting","volume":"15","author":"Vella","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072716592491700_CIT0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection\u2014the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2021072716592491700_CIT0007","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/INF.0000000000000260","article-title":"Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis","volume":"33","author":"Adler-Shohet","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2021072716592491700_CIT0008","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009\u20132012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072716592491700_CIT0009","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/INF.0b013e3181783aca","article-title":"Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003","volume":"27","author":"Feja","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2021072716592491700_CIT0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.109.5.765","article-title":"Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up","volume":"109","author":"Schaaf","year":"2002","journal-title":"Pediatrics"},{"key":"2021072716592491700_CIT0011","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/cit655","article-title":"Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study","volume":"57","author":"Seddon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021072716592491700_CIT0012","volume-title":"Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy Brief No. 1","author":"Seddon","year":"2015"},{"key":"2021072716592491700_CIT0013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3201\/eid2103.141313","article-title":"Moxifloxacin prophylaxis against MDR TB, New York, New York, USA","volume":"21","author":"Trieu","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021072716592491700_CIT0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/thx.2008.100974","article-title":"Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort","volume":"64","author":"Attamna","year":"2009","journal-title":"Thorax"},{"key":"2021072716592491700_CIT0015","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/clinids\/24.6.1264","article-title":"Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin","volume":"24","author":"Ridzon","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2021072716592491700_CIT0016","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/INF.0b013e31829157e9","article-title":"Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom","volume":"32","author":"Williams","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2021072716592491700_CIT0017","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.5588\/ijtld.13.0872","article-title":"Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation","volume":"18","author":"Garcia-Prats","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072716592491700_CIT0018","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"2021072716592491700_CIT0019","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1592\/phco.22.9.701.34065","article-title":"Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population","volume":"22","author":"Lou","year":"2002","journal-title":"Pharmacotherapy"},{"key":"2021072716592491700_CIT0020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.5588\/ijtld.12.0092","article-title":"Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995\u20132010","volume":"16","author":"Denholm","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072716592491700_CIT0021","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018"},{"key":"2021072716592491700_CIT0022","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021072716592491700_CIT0023","first-page":"1112","article-title":"Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases","volume":"14","author":"Mor\u00e1n-Mendoza","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072716592491700_CIT0024","article-title":"TB preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen [manuscript published online ahead of print 12 June 2019]","author":"Malik","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021072716592491700_CIT0025","volume-title":"How to care for people exposed to drug-resistant tuberculosis: a practical guide","year":"2018","edition":"1st ed"},{"key":"2021072716592491700_CIT0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"2021072716592491700_CIT0027","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tube.2015.09.007","article-title":"A review of the use of ethionamide and prothionamide in childhood tuberculosis","volume":"97","author":"Thee","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"2021072716592491700_CIT0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.prrv.2010.09.010","article-title":"Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians","volume":"12","author":"Schaaf","year":"2011","journal-title":"Paediatr Respir Rev"},{"key":"2021072716592491700_CIT0029","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0031-3955(16)38979-9","article-title":"Drug-resistant tuberculosis in pediatrics","volume":"42","author":"Swanson","year":"1995","journal-title":"Pediatr Clin North Am"},{"key":"2021072716592491700_CIT0030","first-page":"278","article-title":"The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa327\/33218934\/ciaa327.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/10\/1709\/39349957\/ciaa327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/10\/1709\/39349957\/ciaa327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:11:30Z","timestamp":1627391490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/10\/1709\/5817711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,4,8]]},"published-print":{"date-parts":[[2021,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa327","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,15]]},"published":{"date-parts":[[2020,4,8]]}}}